Timothy Richardson, PhD
Research Professor of Medicine
- timorich@iu.edu
- Phone
- (317) 274-2730
- Address
-
TO 1038A
CPHR
IN
Indianapolis, IN - PubMed:
-
Bio
Timothy Richardson, PhD, has experience in the fields of medicinal chemistry, pharmacology and drug discovery. He joined the Indiana University School of Medicine in early 2020 as a Senior Research Professor of Medicine in the Division of Clinical Pharmacology.
Before joining IUSM, Dr. Richardson was a Research Fellow at Lilly Research Laboratories, where he made substantial contributions to drug discovery programs that delivered clinical candidates for endocrine, musculoskeletal, and autoimmune diseases. He led technology platform teams focused on Gene Regulation, Epigenetics, and Nuclear Receptors. He also served as a Group Leader in Discovery Chemistry, helping to build a portfolio of small molecule clinical candidates for the Immunology Therapeutic Area. Dr. Richardson finished his career at Lilly as a founding member of the RNA Therapeutics Team facilitating the establishment of internal capabilities as well as an external ecosystem of partnerships, capabilities, and assets for oligonucleotide-based medicines.
Key Publications
Jesudason, Cynthia, D.; Rangel-Barajas, C.; Beach, C. J.; Beck, D. E.; Caballero-Floran, I. H.; Clayton, W. B.; Silva, L. D.; David, J. C.; Doolen, S.; Faulkner, A. N.; Hamdani, A. K.; Huhe, H.; Huynh, K.; Imhoff, R. D.; Javens-Wolfe, J.; Mason, E. R.; Moussaif, M.; Singhal, K.; Soni, D. M.; Buuren-Milne, M. van; Williams, S.-P.; Angus, S. P.; Chu, S.; Dage, J. L.; Hipskind, P. A.; Johnson, T. S.; Kaddurah-Daouk, R.; Lamb, B. T.; Meikle, P. J.; Mesecar, A. D.; Palkowitz, A. D.; Quinney, S. K.; Rizzo, S. J. S.; Oblak, A. L.; Richardson, T. I. Optimization and Characterization of SHIP1 Ligands for Cellular Target Engagement and Activity in Alzheimer’s Disease Models. J. Med. Chem. 2026, 69, 10734–10763.
Richardson, T. I.; Klein, R. C.; Huang, K.; Zhang, J.; Mesecar, A. D.; Dage, J. L.; Clayton, W. B.; Lamb, B. T.; Palkowitz, A. D. Next-Generation Alzheimer's Therapeutics: Target Assessment and Enablement at the Indiana University School of Medicine–Purdue University TREAT-AD Center. Alzheimer's Dement. 2026, 22, e70964.
Bedford, L. M.; Tutrow, K. D.; Hooper, K.; Messenger, E. J.; Hernandez, M.; Lamb, B. T.; Meyer, J. S.; Richardson, T. I.; Bissel, S. J. Alzheimer's Disease-Associated PLCG2 Variants Alter Microglial State and Function in Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells. Alzheimer's Dement. 2025, 21, e70772.
Wang, Y.; Shi, Z.; Weerawarna, P.; Huang, K.; Richardson, T. I.; Wang, Y. Building Explainable Graph Neural Network by Sparse Learning for the Drug-Protein Binding Prediction. J. Comput. Biol. 2025, 32, 632–645.
Ahat, E.; Shi, Z.; Chu, S.; Bui, H. H.; Mason, E. R.; Soni, D. M.; Roth, K. D.; Chalmers, M. J.; Oblak, A. L.; Zhang, J.; Gutierrez, J. A.; Richardson, T. SHIP1 Modulation and Proteome Characterization of Microglia. J. Proteom. 2024, 105198.
Jesudason, C. D.; Mason, E. R.; Chu, S.; Oblak, A. L.; Javens-Wolfe, J.; Moussaif, M.; Durst, G.; Hipskind, P.; Beck, D. E.; Dong, J.; Amarasinghe, O.; Zhang, Z.; Hamdani, A. K.; Singhal, K.; Mesecar, A. D.; Souza, S.; Jacobson, M.; Salvo, J. D.; Soni, D. M.; Kandasamy, M.; Masters, A. R.; Quinney, S. K.; Doolen, S.; Huhe, H.; Rizzo, S. J. S.; Lamb, B. T.; Palkowitz, A. D.; Richardson, T. I. SHIP1 Therapeutic Target Enablement: Identification and Evaluation of Inhibitors for the Treatment of Late-onset Alzheimer’s Disease. Alzheimer’s Dement.: Transl. Res. Clin. Interv. 2023, 9, e12429.
Potjewyd, F. M.; Annor-Gyamfi, J. K.; Aubé, J.; Chu, S.; Conlon, I. L.; Frankowski, K. J.; Guduru, S. K. R.; Hardy, B. P.; Hopkins, M. D.; Kinoshita, C.; Kireev, D. B.; Mason, E. R.; Moerk, C. T.; Nwogbo, F.; Pearce, K. H.; Richardson, T. I.; Rogers, D. A.; Soni, D. M.; Stashko, M.; Wang, X.; Wells, C.; Willson, T. M.; Frye, S. V.; Young, J. E.; Axtman, A. D. AD Informer Set: Chemical Tools to Facilitate Alzheimer's Disease Drug Discovery. Alzheimer's Dement.: Transl. Res. Clin. Interv. 2022, 8, e12246.
Weerawarna, P. M.; Richardson, T. I. Lyn Kinase Structure, Regulation, and Involvement in Neurodegenerative Diseases: A Mini Review. Kinases Phosphatases 2023, 1, 23–38.
Lugar CW, Clarke CA, Morphy R, Rudyk H, Sapmaz S, Stites RE, et al. Defining Target Engagement Required for Efficacy In Vivo at the Retinoic Acid Receptor-Related Orphan Receptor C2 (RORγt). J Med Chem 2021, 64, 5470–84.
| Year | Degree | Institution |
|---|---|---|
| 1997 | PhD | University of Minnesota |
| 1993 | BS | University of Minnesota |
Dr. Richardson leads the IUSM-Purdue TREAT-AD Center, an academic drug discovery center funded by the National Institute for Aging with the goal of diversifying and reinvigorating the Alzheimer’s disease (AD) drug development pipeline. The Center is developing high-quality research tools and drug-like molecules to validate and advance the next generation of drug targets for the treatment of AD. Current efforts are focused on the neuroinflammatory components of neurodegeneration driven by microglia, the non-neuronal, macrophage-like cells that serve as resident immune cells in the brain. We have discovered potent and selective modulators of SHIP1, a phosphatidylinositol phosphatase that plays a key role regulating pathways downstream from TREM2 and the Fcγ receptor FCγRIIB. We are also developing activators of PLCG2, a phospholipase involved in TREM2 and Fcγ receptor mediated signaling. Our hypothesis is that inhibition of SHIP1 or activation of PLCG2 early in disease will increase microglial protective functions and result in a reduced rate of disease progression and cognitive decline in AD patients. Related programs in the lab involve the design, synthesis, conjugation, testing and optimization of oligonucleotides for RNAi-based (siRNA and ASO) knockdown of target genes involved in neuroinflammatory conditions.
Potjewyd FM; Annor-Gyamfi JK; Aubé J; Chu S; Conlon IL; Frankowski KJ; Guduru SKR; Hardy BP; Hopkins MD; Kinoshita C; Kireev DB; Mason ER; Moerk CT; Nwogbo F; Pearce KH; Richardson TI; Rogers DA; Soni DM; Stashko M; Wang X; Wells C; Willson TM; Frye SV; Young JE; Axtman AD; Alzheimer's & dementia (New York, N. Y.) 2022 Apr 20
Potjewyd FM; Annor-Gyamfi JK; Aubé J; Chu S; Conlon IL; Frankowski KJ; Guduru SKR; Hardy BP; Hopkins MD; Kinoshita C; Kireev DB; Mason ER; Moerk CT; Nwogbo F; Pearce KH Jr; Richardson TI; Rogers DA; Soni DM; Stashko M; Wang X; Wells C; Willson TM; Frye SV; Young JE; Axtman AD; Alzheimer's & dementia (New York, N. Y.) 2022 Apr 12
Desc: NRSA Postdoctoral Fellowship
Scope: National
Date: 1997-08-29